Can You Sue a Drug Manufacturer for Failing to Develop a Safer Alternative? The Gilead Tenofovir Decision

If you were prescribed tenofovir disoproxil fumarate — TDF, the antiviral at the heart of HIV treatment regimens such as Viread, Truvada, Atripla, and Complera — and you developed kidney disease or bone loss, you have almost certainly encountered the central allegation of the Gilead litigation: that the manufacturer had a chemically related compound, tenofovir alafenamide (TAF), that appeared safer for kidneys and bones, and that it delayed developing that compound for commercial reasons while patients kept taking the older drug.

That allegation produced a genuinely novel legal theory. Rather than arguing the drug that was sold was defectively designed, the plaintiffs argued the manufacturer was negligent for not developing a different drug sooner. Lawyers began calling it the “duty to innovate.” In August 2026, the California Supreme Court rejected it as a free-standing basis for liability — a decision with immediate consequences for pharmaceutical, medical device, and consumer product claims filed anywhere in California, including in Los Angeles Superior Court, where a substantial share of the state’s mass tort inventory sits.

This guide explains, in plain English, what the court actually decided, what it did not decide, which theories still give injured Californians a viable path to compensation, and what you should do right now if you believe a prescription drug harmed you.

What the Gilead Tenofovir Case Was Actually About

The underlying litigation was brought by thousands of plaintiffs who took TDF-based HIV medications and alleged they suffered chronic kidney disease, reduced kidney function, osteopenia, osteoporosis, and in some cases fractures. TDF was, and remains, an enormously effective antiviral. The dispute was never about whether it worked. It was about renal and skeletal toxicity, and about timing.

Plaintiffs alleged that during the development of TDF, the manufacturer identified TAF — a prodrug delivering the same active agent at far lower plasma concentrations, with a correspondingly better kidney and bone profile — and then paused its development, only bringing TAF products to market years later, closer to the expiration of the commercial exclusivity on the older franchise. The plaintiffs’ core negligence theory was not that TDF was defective in design. It was that a reasonable manufacturer, knowing what this one knew, would have moved the safer compound forward, and that the delay itself was negligent conduct causing avoidable harm.

That framing was deliberate, and it was aggressive. Under the long-standing California rule descending from Brown v. Superior Court (1988) 44 Cal.3d 1049, prescription drugs are not subject to ordinary strict liability design-defect analysis — a policy choice made because imposing that liability would discourage the development of beneficial medicines. The “duty to innovate” theory attempted to route around Brown by pleading negligence based on the drug that was never sold.

How the case moved through the courts

Why the Court Said No to a “Duty to Innovate”

California duty analysis runs through Rowland v. Christian (1968) 69 Cal.2d 108, which asks courts to weigh foreseeability of harm, certainty of injury, the closeness of the connection between conduct and injury, moral blame, the policy of preventing future harm, the burden on the defendant, and the consequences to the community. Applied to a claimed duty to bring a different drug to market, several of those factors cut hard against the plaintiffs:

• Boundlessness. Every manufacturer’s pipeline contains compounds that were shelved, deprioritized, or reformulated. A duty to commercialize the safest option in a pipeline has no natural stopping point, and no principled way to identify which candidate, at which stage, triggered it.
• Judicial competence. Deciding whether a molecule with promising early data should have advanced requires second-guessing dose-ranging studies, manufacturing scale-up, formulation stability, regulatory strategy, and clinical trial design — judgments a jury is poorly positioned to make years later with hindsight.
• Conflict with the regulatory scheme. The FDA, not a civil jury, governs which drugs enter the market and on what timeline. A tort duty layered on top would create competing and potentially contradictory obligations.
• Perverse incentives. Punishing a company for internally identifying a safer candidate discourages exactly the early safety research the law wants to encourage — the same logic that produced the Brown rule in the first place.

The court’s reasoning is not a statement that the plaintiffs were unharmed or that the conduct alleged was admirable. It is a narrower institutional judgment: tort law polices the product a company put into the stream of commerce, not the product it declined to build.

What This Does Not Change: The Claims That Still Work

This is the part that matters most to injured people, and it is the part most commonly misreported. The decision eliminated one theory. It left the entire conventional architecture of California pharmaceutical liability intact.

1. Failure to warn — still the centerpiece

For prescription drugs, failure to warn is the dominant theory in California. A manufacturer must warn of risks that were known or reasonably scientifically knowable at the time of distribution. Under the learned intermediary doctrine the warning runs to the prescribing physician, so the practical questions become: what did the label say about renal and bone toxicity, when did it say it, what did the company’s own pharmacovigilance data show, and would an adequately warned physician have prescribed differently or monitored more closely? Nothing in the Gilead ruling weakens this claim. If anything, it concentrates litigation on it.

2. Negligent design of the drug that was sold

Brown bars strict liability design-defect claims for prescription drugs, but it does not immunize negligent design. A claim that the formulation, dosing, or delivery mechanism of the marketed product fell below the standard of care remains available — the difference is that it must be about the marketed product, not a hypothetical replacement.

3. Negligent testing and post-market surveillance

Manufacturers have continuing obligations to monitor adverse event signals after approval and to act on them. Failing to investigate a renal toxicity signal, or failing to update labeling and communicate with prescribers once a signal emerges, is conduct directed at the product actually sold.

4. Fraudulent concealment and negligent misrepresentation

Where a company affirmatively downplays known risks in marketing, detailing to physicians, or published materials, misrepresentation claims are independent of any duty-to-innovate theory. These claims also matter for the statute of limitations, because concealment can support tolling.

5. Manufacturing defect

If a specific lot deviated from specification, strict liability still applies in full. Brown has never shielded manufacturing defects.

Why This Matters Specifically in Los Angeles

Los Angeles County is not an incidental venue for this litigation. Several features of the region make it central:

• Patient population and prescribing volume. Los Angeles has one of the largest HIV care infrastructures in the United States, anchored by county health facilities, community clinics in Hollywood, West Hollywood, Long Beach, and South LA, and major academic centers including UCLA and USC. TDF-based regimens were prescribed here at enormous scale over more than a decade.
• Complex litigation departments. Los Angeles Superior Court’s complex civil program at the Spring Street Courthouse regularly manages coordinated pharmaceutical proceedings. California’s Judicial Council coordination process (JCCP) frequently sends drug cases to LA or to neighboring counties, meaning appellate developments translate quickly into case management orders that affect hundreds of individual plaintiffs at once.
• Records fragmentation. LA patients often rotate among county clinics, private practices, urgent care, and hospital systems. Reconstructing an unbroken prescription and lab history — serum creatinine, eGFR trends, DEXA scans — typically requires subpoenas to five or more custodians. This takes months, and it is the single most common reason otherwise strong claims stall.
• Statutory environment. California’s comparative fault rules, its two-year injury deadline, and its treatment of the discovery rule for latent injuries all shape strategy differently than in other states where parallel cases are pending.

Deadlines: The Issue That Quietly Kills the Most Claims

California’s general personal injury statute of limitations is two years from the date the cause of action accrues (Code Civ. Proc. § 335.1). For drug injuries, accrual is rarely the date you swallowed the first pill. The discovery rule generally delays accrual until a plaintiff knows, or through reasonable diligence should know, of the injury and its wrongful cause.

That sounds forgiving. In practice it is treacherous, because defendants argue the clock started at the first abnormal lab result, the first nephrology referral, the first news report or television advertisement about the drug, or the date the label changed. Once a court accepts an early trigger date, the case is over regardless of its merits.

Evidence That Strengthens a Pharmaceutical Injury Claim

Whatever the governing theory, these are the materials that decide outcomes. Gather what you can now:

1. Complete pharmacy dispensing records — every fill, every NDC number, every prescriber, ideally from each pharmacy chain you used. These establish exposure and duration better than any other document.
2. Serial laboratory values — serum creatinine and eGFR over time, phosphate, urine protein. A downward eGFR trend that reverses after discontinuation is powerful causation evidence.
3. Bone density imaging — DEXA scans with T-scores and Z-scores, plus any fracture imaging.
4. Specialist records — nephrology, endocrinology, infectious disease notes, especially any note attributing findings to medication.
5. Switch documentation — the date and clinical rationale for any change from a TDF-based regimen to a TAF-based one.
6. Damages proof — out-of-pocket medical costs, wage loss, and a written record of how the condition changed daily life. Non-economic damages in California are proven through specifics, not adjectives.

How Pharmaceutical Claims Differ From Everyday Injury Cases

If your prior experience with the civil system is a collision on the 405 or a fall in a grocery store, the differences are significant. In a Los Angeles car accident case, liability often turns on a police report, photographs, and a handful of witnesses, and the defendant is an insurer with defined policy limits. In a slip and fall or premises liability case, the fight is usually about notice — how long the hazard existed and whether the owner should have found it.

Pharmaceutical cases are different in kind. Causation is established through epidemiology and differential diagnosis rather than eyewitness testimony. The key documents are internal corporate research files obtained in discovery. Expert costs run into six figures. Cases are frequently coordinated with hundreds of others, which means your individual timeline is partly governed by rulings in cases you are not personally involved in. This is why firm selection and early case evaluation matter more here than in almost any other category of injury claim.

The Broader Signal for California Product Liability

The reasoning here reaches past pharmaceuticals. Any claim built on the premise that a company should have designed and released a fundamentally different, safer product now faces the same structural objection: courts are reluctant to convert business and engineering roadmaps into tort duties. Expect defendants in medical device, automotive, industrial equipment, and chemical exposure cases to cite this decision.

The countervailing point is equally important, and plaintiffs’ lawyers should press it. What a company learned while developing an alternative does not become privileged or irrelevant. Internal data showing that a company understood the toxicity mechanism of its marketed product remains squarely admissible on knowledge — which is the foundation of every failure-to-warn claim. The alternative-compound research does not create a duty; it proves what the company knew about the drug it kept selling. That distinction is subtle, and it is where these cases will now be won or lost.

What To Do If You Think a Drug Injured You

1. Do not stop a prescribed medication on your own. Speak with your treating physician first. Abrupt discontinuation of antiviral therapy carries serious risks that dwarf any litigation consideration.
2. Request your complete records now. California gives patients a right to copies of their medical records; pharmacies will typically produce a multi-year dispensing history on request.
3. Write down your timeline while memory is fresh: when you started, who prescribed it, when symptoms appeared, what you were told.
4. Do not sign anything from a manufacturer or an insurer and do not give a recorded statement without counsel.
5. Get evaluated by a lawyer immediately. Even if you believe you may be past a deadline, tolling doctrines sometimes apply — but only a review of your specific facts can tell you.

Frequently Asked Questions

Talk to InjuryAllies

The law in this area moved in 2026, and it will keep moving. What has not changed is that a company that sells a drug is answerable for what it knew about that drug and what it told the doctors who prescribed it. If you took a TDF-based medication and developed kidney disease, bone loss, or fractures — or if any prescription drug has injured you or a family member — find out where you stand before a deadline decides for you.

Call (323) 372-1216 or use the form below. Consultations are free and confidential, and you owe nothing unless we recover for you.